Table 2. Best tumor responses for patients with advanced hepatocellular carcinoma who underwent either apatinib or sorafenib.
| Response | Apatinib group (n=26) [cases (%)] | Sorafenib group (n=46) [cases (%)] | P value |
|---|---|---|---|
| Objective response | 5 (19.2) | 1 (2.2) | 0.012 |
| Disease control | 15 (57.7) | 23 (50.0) | 0.530 |
| Complete response | 0 | 0 | 1.000 |
| Partial response | 5 (19.2) | 1 (2.2) | 0.012 |
| Stable disease | 10 (38.5) | 22 (47.8) | 0.442 |
| Progressive disease | 11 (42.3) | 23 (50.0) | 0.530 |
P values were calculated using a two-sided Chi-square test